Cabozantinib Superior to Sunitinib for Metastatic RCC Cabozantinib Superior to Sunitinib for Metastatic RCC
Cabozantinib provides significantly better progression-free survival (PFS) and objective response rates (ORR) in patients with metastatic renal cell carcinoma (RCC) of poor or intermediate risk, according to results from the Alliance A031203 CABOSUN trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Health | Hematology | Kidney Cancer | Renal Cell Carcinoma